Clinical Research Division, Fred Hutch
Dr. Damian Green develops new immunotherapies that harness the power of the immune system to treat and ultimately eradicate multiple myeloma and lymphoma. A major research focus is radioimmunotherapy, in which radioactive particles are linked to cancer-targeting molecules called antibodies to deliver deadly radiation straight to cancer cells while sparing healthy tissues. Dr. Green also studies a type of immunotherapy called bispecific antibody therapy in which a two-pronged antibody brings together cancer-killing immune cells and cancer cells. Another major focus of his work is the development and clinical evaluation of a form of genetically engineered T-cell therapy (called CAR T-cell therapy) for patients with myeloma.
University of Washington School of Medicine
Seattle Cancer Care Alliance
Deputy Director for Myeloma
Seattle Translational Tumor Registry (STTR)
The Ohio State University College of Medicine, 2000, M.D.
The Ohio State University Department of Internal Medicine, 2003 (Residency) 2004 (Chief Resident)
Fred Hutchinson Cancer Research Center and University of Washington Medical Oncology Fellowship Program, 2007
Dr. Green’s research is supported by three competitive federal grants on which he is lead investigator and through a variety of non-profit research foundation initiatives focused on improving stem cell transplant outcomes, delivering targeted radiation to tumor cells and improving the efficacy of chimeric antigen receptor (CAR) T-cell therapy. He is the principal investigator on numerous clinical trials, including studies to evaluate CAR T-cell therapy in multiple myeloma. Dr. Green is also a lead investigator on a multi-center network grant through the Multiple Myeloma Research Foundation (MMRF) designed to define optimal tumor and host signatures for immunotherapy of multiple myeloma. He is also co-leader on an initiative with the Allen Institute for Immunology focused on characterizing the dysregulation of immune function in multiple myeloma.
In addition, he is co-investigator on over 20 clinical trials for patients with multiple myeloma or lymphoma.
Dr. Green’s laboratory and clinical research is focused on developing new immunotherapeutic approaches to treat and ultimately eradicate multiple myeloma and lymphoma.
Study Number: 9847
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210.